65. Primary immunodeficiency Clinical trials / Disease details

Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01985373 (ClinicalTrials.gov)	December 2013	31/10/2013	Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml	Pharmacokinetics and Safety of the Intravenous Human Immunoglobulin Product Nanogam 100 mg/ml	Primary Immunodeficiency	Drug: Intravenous immunoglobulin infusion	Sanquin	NULL	Completed	18 Years	N/A	Both	23	Phase 3	Netherlands
2	EUCTR2012-005727-32-NL (EUCTR)	25/07/2013	23/05/2013	The pharmacokinetics (the behaviour in the body) and safety of the intravenous immunoglobulin product Nanogam 100 mg/ml	Pharmacokinetics and safety of the intravenous human immunoglobulin product Nanogam 100 mg/ml - PK and safety of Nanogam 100 mg/ml	Primary a- or hypogammaglobulinemia MedDRA version: 14.1;Level: LLT;Classification code 10010112;Term: Common variable immunodeficiency;System Organ Class: 100000004870 MedDRA version: 14.1;Classification code 10010509;Term: Congenital hypogammaglobulinemia;System Organ Class: 100000004850 MedDRA version: 14.1;Classification code 10071133;Term: Congenital agammaglobulinemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Nanogam 100 mg/ml INN or Proposed INN: HUMAN NORMAL IMMUNOGLOBULIN (IV) Other descriptive name: IVIG Trade Name: Nanogam® 50 mg/ml INN or Proposed INN: HUMAN NORMAL IMMUNOGLOBULIN (IV) Other descriptive name: IVIG	Sanquin Blood Supply Foundation	NULL	Not Recruiting			Female: yes Male: yes			Netherlands